Member Info for LovableLumax

2Phevs are you doing a pump and dump like you did last year? I guess with 7m to sell you are gonna be busy.

They sold 250m shares at 3p just 12 months ago and given the pipeline and possibly break even end of next year they will need to raise again in less than 12 months.2phevs and others dangerous and hyping and gullible newbies bought in and now underwater. It's currently oversold so should bounce but it did that last year went above 3p raise to 4p and then of course fell. My prediction is the same will happen here. If 2phevs is right and Amazon is now working with Mirriad than it'll fly but the huge dilution and raise more than bizarre.

Also, the pipe and this doesn;t sound like breakeven next year -

continue along the steady path towards programmatic, which has always been identified as the catalyst for future growth.

Based on this very favourable three-weekly dosing safety profile, Avacta commenced a two-weekly dosing safety study in the US on the basis that this is likely to lead to better efficacy. Three patients have now been dosed in cohort 1 (160 mg/m2) of the two-weekly dose escalation study in the US and Avacta has received regulatory and ethics approval to open sites in the UK in the two-weekly arm. Avacta anticipates that the SMDC will review the two-weekly cohort 1 data by the end of April.

The combined data from the three-weekly and two-weekly studies will provide information to allow the Company to define the dose and schedule to be used in future efficacy studies. Patients can be dosed in parallel in the two-weekly dose escalation study and Avacta remains on track to begin the dose expansion efficacy study in the second half of 2024. The data from the expansion study will be used to inform the optimal choice of a single orphan indication for the Phase 2 efficacy study which will follow on immediately.

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

"We are extremely pleased with the continued excellent progress of AVA6000 in the Phase 1a dose escalation study. These emerging data clearly demonstrate that the pre|CISION? peptide drug conjugate platform is functioning in the way it was designed and is capable of targeting the release of a cancer therapy to the tumor. Targeted therapy that spares healthy tissues is a holy grail of oncology drug development and we believe we have a unique platform to target FAP-rich tumor tissues to deliver significantly better outcomes for patients and substantial value to our shareholders.

"The continuing validation of the pre|CISION? platform we are seeing in the clinic underlines our confidence in the significant opportunity to apply pre|CISION? to a range of warheads, including those much more potent than doxorubicin.

We are now in a very strong position to deliver significant clinical and commercial milestones relating to AVA6000 and the wider pre|CISION? platform, and we are looking forward to providing a further detailed update on the clinical trial at the American Association for Cancer Research meeting in April."

Lee Cranmer MD, PhD, FACP, Curtis and Elizabeth Anderson Endowed Professor in Sarcoma Research, University of Washington and Professor and Director of Sarcoma Oncology, Fred Hutchinson Cancer Center, commented:

"I am encouraged by the initial data with AVA6000 in the Phase 1 trial and look forward to working with my fellow investigators and our collaborators at Avacta to understand better the optimal dosing for this novel approach to targeted cancer therapy."

The fact they have gone for unweighted should concern us as the weighted pipe must be pretty grim -

Unweighted Sales Pipeline:

In an unweighted sales pipeline, every deal is considered equally likely to close, regardless of its stage in the sales funnel.

This approach looks at the full potential value of opportunities at each stage.

For example, whether you’ve just made initial contact via a cold call or if the prospect is ready to sign, all deals are treated equally.

However, this can lead to inflated revenue forecasts if high-value opportunities fall through1.

Weighted Sales Pipeline:

A weighted sales pipeline takes into account the probability of closing for each deal based on its stage.

Deals further along in the pipeline are given more weight in sales forecasting because they have a higher likelihood of closing.

You need to look at what the number of shares in issue was when Stephan took over, what the share price was and what the turnover was. Also worth looking at the huge sums he has taken out of the business in salary and bonuses, insane. What you'll notice is the share price has collapsed, turnover stagnated and now less than $2m and number of shares in issue gone up 10 fold to soon be 1bn. Pipeline, unweighted (I have to keep reminding you!) which means anything no matter how remote is only £2.6m. You continue to lap up what the CEO says. My bet is when this goes under he'll have rinsed enough money from here and will retire

Seems highly unlikely they've forgotten to schedule a meeting given they want to press on. I believe every RNS relating to dosing has been issued on a Weds or Thurs so hopefully we get news this week.

Then if mirriad such a moat/IP why not chuck £50m to buy the lot and also have one up on rivals as well as the platform? Mirriad was up for sale last year and had no interest.

BV it depends on if they intend on an RNS for safety committee happy to proceed, 1st patient dosed or 3rd patient dosed.

stephan is a blagger. soon to have 1bn shares in issue and burning nearly £800k a month, break even if at all end of next year so another raise needed next year. £2.6m total pipe and you continue to swallow his bull ****. he was paying himself nearly £1m not long ago, nearly 20% of what they just raised!! it’s a lifestyle business that stephan is milking.

I’m not backtracking just reading between the lines. The co mentions Amazon and NBCU and also states competitor risk has increased. I linked them. This is from their RNS albeit different sections -

This was from 12 months ago at the 3p raise - In the event that the Company is unable to meet such obligations as a result of the failure of the Fundraising to complete and in the event that the Company is unable to secure alternative sources of funding, the Directors believe that it is unlikely that the Company will be able to continue as a going concern and it is highly likely that the Directors would (in order to fulfil their duties to the Company's creditors and to other applicable stakeholders) seek to place the Company into some form of insolvency proceeding

The announcements made by Amazon and NBCU that they were, or intended, to enter the in-content advertising market;

The Directors expect other major media and adtech companies to enter the in-content market over the next twelve months. The Directors believe that ultimately this will lead to an industry-wide development and adoption of in-content advertising as a new advertising format.

There are, however, emerging competitors who provide similar services (in some respects) to those provided by the Company and several who have longer established business models with larger revenue streams operating in adjacent business sectors. It is also possible for very large and well-resourced organisations who sell advertising products as part of their core business to see the market potential that the Company sees. While the Directors believe that replication of the Company's platform is complex and a level of protection is afforded by various intellectual property protections, including patents, copyright, trademarks, trade secrets and contractual provisions, to preserve its intellectual property rights, an organisation with the ability to invest and devote resource to the development of an advertising product could ultimately replicate the service provided by the Company. Many of the Company's competitors and potential competitors have significantly greater financial, technical, marketing or service resources than the Company and have a larger base of products, longer operating histories and/or greater name recognition. In addition, the Company's competitors may be able to respond more quickly than the Company can to changes in partner requirements and devote greater resources to the enhancement, promotion and sale of their products and to the development of new products.

Amazon will be developing its own for Prime and I suspect not reselling for others to use. The point I made earlier stands -

The fact competitors are coming is good as it validates the space. The fact one of these monsters doesn’t buy mirriad for say £50m means the IP isn’t creating a moat. Mirriad has stagnated and it seems highly unlikely they will be part of the pie will which be massive in 3-5 years. The big boys will want the revenue stream to themselves. No way will they let a little UK minnow take a slice. Alarm bells rang when no one came forward when mirriad up for sale last year which tells me they can and are developing their own.

The Directors expect other major media and adtech companies to enter the in-content market over the next twelve months. The Directors believe that ultimately this will lead to an industry-wide development and adoption of in-content advertising as a new advertising format.

There are, however, emerging competitors who provide similar services (in some respects) to those provided by the Company and several who have longer established business models with larger revenue streams operating in adjacent business sectors. It is also possible for very large and well-resourced organisations who sell advertising products as part of their core business to see the market potential that the Company sees. While the Directors believe that replication of the Company's platform is complex and a level of protection is afforded by various intellectual property protections, including patents, copyright, trademarks, trade secrets and contractual provisions, to preserve its intellectual property rights, an organisation with the ability to invest and devote resource to the development of an advertising product could ultimately replicate the service provided by the Company. Many of the Company's competitors and potential competitors have significantly greater financial, technical, marketing or service resources than the Company and have a larger base of products, longer operating histories and/or greater name recognition. In addition, the Company's competitors may be able to respond more quickly than the Company can to changes in partner requirements and devote greater resources to the enhancement, promotion and sale of their products and to the development of new products.

I said competitor risk had increased which it says in the annual report. I also said they mentioned Amazon and NBCU had entered the mix which they have (Google it). You now believe that Amazon has stopped developing its own and is working or testing mirriad. I doubt it but if that is the case it’s amazing although bizarre Amazon wouldn’t just buy mirriad and encorporate the IP with its own.

The fact that you have seemingly only just read important RNSs now is poor and the fact you were hoping this to unsuspecting investors/traders without doing basic research also poor. Given the cash burn, really poor pipeline it’s highly likely another raise needed within 12 months and given history it’ll be a lot lower than now unless something drastic happens with revenues.

They are. Look at the annual report, there is a risk section and the risk has materially increased.

LOTM if Amazon etc have shelved their platforms to work with mirriad then that’s huge and they do clearly have a moat. We’ll see but surely they’d just buy mirriad rather than letting all their dev work go to waste. Anyway, we’ll see.

The fact competitors are coming is good as it validates the space. The fact one of these monsters doesn’t buy mirriad for say £50m means the IP isn’t creating a moat. Mirriad has stagnated and it seems highly unlikely they will be part of the pie will which be massive in 3-5 years. The big boys will want the revenue stream to themselves. No way will they let a little UK minnow take a slice. Alarm bells rang when no one came forward when mirriad up for sale last year.

This was from 12 months ago at the 3p raise - In the event that the Company is unable to meet such obligations as a result of the failure of the Fundraising to complete and in the event that the Company is unable to secure alternative sources of funding, the Directors believe that it is unlikely that the Company will be able to continue as a going concern and it is highly likely that the Directors would (in order to fulfil their duties to the Company's creditors and to other applicable stakeholders) seek to place the Company into some form of insolvency proceeding

The announcements made by Amazon and NBCU that they were, or intended, to enter the in-content advertising market;

The Directors expect other major media and adtech companies to enter the in-content market over the next twelve months. The Directors believe that ultimately this will lead to an industry-wide development and adoption of in-content advertising as a new advertising format.

There are, however, emerging competitors who provide similar services (in some respects) to those provided by the Company and several who have longer established business models with larger revenue streams operating in adjacent business sectors. It is also possible for very large and well-resourced organisations who sell advertising products as part of their core business to see the market potential that the Company sees. While the Directors believe that replication of the Company's platform is complex and a level of protection is afforded by various intellectual property protections, including patents, copyright, trademarks, trade secrets and contractual provisions, to preserve its intellectual property rights, an organisation with the ability to invest and devote resource to the development of an advertising product could ultimately replicate the service provided by the Company. Many of the Company's competitors and potential competitors have significantly greater financial, technical, marketing or service resources than the Company and have a larger base of products, longer operating histories and/or greater name recognition. In addition, the Company's competitors may be able to respond more quickly than the Company can to changes in partner requirements and devote greater resources to the enhancement, promotion and sale of their products and to the development of new products.

*spelled out

LOTM I can only assume you cannot read between the lines and need it spelt out. As I posted the potential of Mirriad massive as the VPP space will be massive so that’s why mirriad has signed demand and supply side partners for years (see Disney 3 years ago). The point I’m labouring is Mirriad’s moat/IP isn’t deterring competitors and some massive players who could gobble mirriad up if necessary which is clearly isn’t. Mirriad has talked potential for years, same patter and my point is the revenues in as few years will be huge and my bet is mirriad wont be around as will have gone under or bought out (less likely as would have happened).

Are you not concerned they are still burning nearly £800,000 a month, have an unweighted pipeline for the rest of the year of £2.6m which is awful and they’re more than likely gonna raise again within 12 months. If they can.

I understand you’re new here and underwater but you need to be realistic and hopefully your days of hyping to naive investors over.

You also forget mirriad had a for sale sign up last year and they said no one was interested. VPP will be massive in a few years so huge money. If mirriad had a most so IP stopped others from getting in on it they’d have been bought last year or even now for less than £50m or 10p a shares feck all to big boys.